All News

The benefits of taking aspirin to prevent a second or subsequent cardiovascular event have been well established in previous studies but the effectiveness of taking aspirin to prevent a first cardiovascular event has been unclear, despite 30 years of randomized clinical trials.

The data demonstrated that the lotion resulted in statistically significant reductions in both inflammatory and noninflammatory lesions compared to vehicle.

This week's featured pharmacist is Lisa Lohr, Pharm D, BCPS, BCOP, a Specialty Medication Therapy Management pharmacist specializing in oncology care.

Improved access to uniform cancer care in rural areas could help reduce disparities seen between rural and urban patients.

Officials with the FDA have approved the first monoclonal antibody, lanadelumab (Takhzyro, Shire) for the treatment of patients 12 years and older with types 1 and 2 hereditary angioedema (HAE), according to the agency.

Top news of the day from across the health care landscape

Top news of the day from across the health care landscape

"I’m always working on making things better for the patients. Chemotherapy can be quite a scary kind of treatment."

Molecular link found between aging and a major genetic cause of 2 neurodegenerative disorders.

Top news of the week from Specialty Pharmacy Times.

Officials with the FDA announced Thursday approval of lanadelumab (Takhzyro) for treatment of hereditary angioedema (HAE).

Lanadelumab (Takhzyro) is the first monoclonal antibody for the treatment of patients 12 years and older with types 1 and 2 hereditary angioedema.

A new HIV therapy demonstrated its efficacy in reducing the virus and boosting immunity in drug-resistant patients, according to a recent published study.

Buprenorphine with naloxone (Suboxone), an established treatment for opioid use disorder, has been increasingly used in states that chose to expand Medicaid eligibility under the Affordable Care Act, according to the results of a recent study.